EUCTR2007-001264-72-GB
Active, not recruiting
Phase 1
A Phase II Trial of Erlotinib as first line therapy in Non- Small Cell Lung Cancer over-expressing EGFR - Study of targeted Erlotinib treatment for Non-small cell lung cancer
Oxford Radcliffe Hospitals NHS Trust0 sites35 target enrollmentApril 17, 2007
ConditionsStage IIIb/IV non-small cell lung cancer (NSCLC) tumours that over-express EGFRMedDRA version: 9.1 Level: LLT Classification code 10025054 Term: Lung cancer non-small cell stage IIIBMedDRA version: 9.1 Level: LLT Classification code 10029522 Term: Non-small cell lung cancer stage IV
DrugsTarceva
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Stage IIIb/IV non-small cell lung cancer (NSCLC) tumours that over-express EGFR
- Sponsor
- Oxford Radcliffe Hospitals NHS Trust
- Enrollment
- 35
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically or cytologically proven NSCLC, Stage IIIb/IV
- •Immunocytochemical evidence of EGFR over expression (\+\+ or \+\+\+) from diagnostic tissue (e.g. bronchoscopic tumour samples core biopsies, fine needle aspirates\-FNA).
- •Life expectancy of at least 12 weeks
- •World Health Organisation (WHO) performance status of 0\-2
- •Haematological and biochemical indices within the ranges shown below. These measurements must be performed within two weeks before the patient goes on study. Haemoglobin (Hb)\=9\.0 g/dl.
- •Neutrophils\=1\.5 x 10 to the power 9/L. Platelets\=100 x 10 to the power 9/L. Serum bilirubin \=1\.5 x upper normal limit.
- •Aspartate amino\-transferase (AST) \= 2\.5 x upper limit of normal (ULN).
- •Calculated creatinine clearance \=50 ml/min.
- •18 years or over
- •Written (signed and dated) informed consent and be capable of co\-operating with treatment and follow\-up
Exclusion Criteria
- •Previously treated with combination chemotherapy as first line treatment of NSCLC.
- •Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or chemotherapy during the previous four weeks.
- •Current malignancies at other sites, with the exception of adequately treated cone\-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy and are deemed at low risk for recurrence, are eligible for the study.
- •Known primary brain tumours or brain metastases.
- •Ability to become pregnant (or already pregnant or lactating). However, those female patients who have a negative serum or urine pregnancy test before enrolment and agree to use appropriate medically approved contraception for four weeks before starting trial treatment, during the trial and for six months afterwards are considered eligible.
- •At high medical risk because of non\-malignant systemic disease including active uncontrolled infection.
- •Known to be serologically positive for Hepatitis B, Hepatitis C or Human Immunodeficiency Virus (HIV).
- •Any other condition which in the Investigator’s opinion would not make the patient a good candidate for the clinical trial.
- •Anticoagulant, antifibrinolytic therapy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Phase II study of erlotinib as first line chemotherapy in patients with lung adenocarcinoma with brain metastasis and EGFR mutations.lung adenocarcinomaJPRN-UMIN000013502Osaka city General Hospital25
Completed
Phase 2
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002716Central Japan Lung Study Group (CJLSG)29
Completed
Phase 2
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002692Central Japan Lung Study Group (CJLSG)54
Recruiting
Phase 2
A Phase II Study of Erlotinib for previously treated Non-Small Cell Lung Cancer PatientsObjective of the study is to investigate efficacy and safety of Erlotinib for previously treated non-small cell lung cancer patients.JPRN-UMIN000004680Tottori University, Faculty of Medicine,Division of Medical Oncology and Molecular Respirology Department of Multidisciplinary Internal Medicine27
Completed
Phase 2
Phase II study of erlotinib monotherapy for patients with advanced stage of non-small cell lung cancer, undetectable epidermal growth factor receptor (EGFR) mutations by PNA LNA PCR clamp method, but positive immuno-staining with anti-EGFR mutation-specific antibodies.on-small cell lung cancerJPRN-UMIN000014299Dept. of Respiratory Medicine, Osaka Police Hospital7